Transjugular and Transfemoral Embolization for Varicocele.
Condition(s) studied
Investigational drug(s) / intervention(s)
Percutaneous Varicocele Embolization Using N-Butyl Cyanoacrylate (NBCA): Percutaneous varicocele embolization will be performed under fluoroscopic guidance using a transvenous approach, either transfemoral or transjugular, according to the venous anatomy and operator preference. Selective catheterization of the internal spermatic vein will be performed, followed by embolization using N-butyl cyanoacrylate (NBCA) glue. Technical success will be assessed by completion venography demonstrating occlusion of the targeted varicocele veins and absence of significant residual venous reflux.
Study summary
This prospective study will evaluate two different approaches for performing embolization to treat varicocele, a condition in which the veins around the testicle become enlarged. Thirty patients with varicocele will undergo embolization using either a transjugular approach, through a vein in the neck, or a transfemoral approach, through a vein in the groin. The choice of approach will depend on the patient's venous anatomy and the feasibility of the procedure. Patients will be followed up at one and three months after the procedure to assess treatment effectiveness, symptom improvement, and any complications.
Eligibility
Primary outcome measure(s)
- Change in Pain Intensity Measured by the Visual Analog Scale (VAS). — 1 month after the procedure
Pain intensity will be assessed using the Visual Analog Scale (VAS), ranging from 0 to 10, where 0 indicates no pain and 10 indicates the worst imaginable pain. A decrease in the VAS score indicates improvement in pain. The change in VAS score from baseline to 1 month after varicocele embolization will be assessed.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Sohag University - Faculty of Medicine | Sohag | Sohag Governorate | Recruiting |
More Sohag University trials in Egypt
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07764900 on ClinicalTrials.gov ↗ ← All trials in Egypt